Immatics N.V. reported its fourth‑quarter 2025 results on March 5 2026, posting a net loss of $0.34 per share—an improvement of 29% over the consensus estimate of a $0.48 loss. Revenue reached $23.005 million, beating the $12.180 million estimate and marking a significant upside in top‑line performance.
Revenue was down $37.03 million year‑over‑year, reflecting the termination of collaboration agreements in 2024 that had previously contributed non‑cash revenue. The remaining sales were driven by stronger uptake of the company’s TCR bispecific platform, which helped offset the decline and secure the revenue beat.
The loss margin narrowed because Immatics reduced one‑time charges and improved operating efficiency. While the company remains in a loss position, the tighter cost base and lower non‑recurring expenses contributed to the improved earnings per share.
Full‑year 2025 figures illustrate the broader context: revenue fell to $56.8 million from $183.1 million in 2024, and the net loss widened to $230.8 million from a $17.9 million profit. Cash and cash equivalents stood at $551.4 million as of December 31 2025, a cushion that extends the company’s runway into 2028 after a $125 million public offering completed on December 8 2025.
Immatics’ clinical pipeline remains a key growth driver. The Phase 3 SUPRAME trial is expected to deliver interim and final analyses in 2026, with a BLA submission targeted for the first half of 2027 and a commercial launch in the second half of 2027. The IMA402 dose‑expansion study continues to progress, and the flagship cell therapy, anzu‑cel (IMA203), is in Phase 3 for melanoma and is still pre‑revenue.
Harpreet Singh, Ph.D., CEO and Co‑Founder, said, "Following a year of strong execution and data updates across our entire PRAME franchise, Immatics is entering 2026 with multiple high‑impact milestones ahead, including advancing our PRAME cell therapy, anzu‑cel, towards approval."
The company also maintains a collaboration with Moderna for a combination trial of anzu‑cel and mRNA‑4203, underscoring its strategy to accelerate clinical development and broaden therapeutic indications.
While the earnings beat signals disciplined cost management and a growing product pipeline, the continued loss and declining revenue highlight the need for sustained funding and milestone achievements to maintain investor confidence.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.